drugset / Trial / NCT00925769
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This 2 part study will evaluate the safety and efficacy of a combination of Avastin, Tarceva and Xeloda (ATX) as second-line treatment in patients with locally advanced and/or metastatic pancreatic cancer. In the first part of the study, cohorts of patients will receive escalating doses of combination treatment to determine the maximum tolerated dose. The recommended dose will be used in the second part of the study to determine the efficacy of the ATX regime, in terms of its effect on disease progression. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Timeline
- Start
- 2009-01
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Capecitabine | Small molecule | 500 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 650 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 750 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 900 mg/m2 | — |
| Subject | Erlotinib | Small molecule | 100 mg | — |
| Subject | Erlotinib | Small molecule | 150 mg | — |